ReviewTopics in current chemistry (Cham)2026
Advances in MOF-Based Transdermal Drug Delivery Systems: Mechanisms, Applications, and Future Prospects.
Review in Topics in current chemistry (Cham), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transdermal drug delivery offers a noninvasive alternative to conventional administration by avoiding gastrointestinal degradation and hepatic first-pass metabolism. However, its broader clinical application remains limited by the barrier function of the stratum corneum and insufficient drug accumulation within target tissues. Metal-organic frameworks (MOFs), characterized by their high surface area, tunable pore structures, and versatile surface chemistry, have recently emerged as promising platforms for transdermal drug delivery. This review summarizes the key advantages of MOF-based transdermal systems, including high drug-loading capacity, particularly for hydrophobic compounds and macromolecules, programmable multidrug delivery, favorable biocompatibility, and the integration of diagnostic and therapeutic functions with complementary physical treatment modalities. We further discuss recent advances in the rational design of MOF-based transdermal platforms across major biomedical applications, including diabetic wound management, skin regeneration, skin cancer therapy, and cosmetic delivery. Despite these advances, clinical translation remains challenged by insufficient long-term biosafety evaluation, incomplete understanding of degradation behavior and biodistribution, limited manufacturing scalability, and regulatory requirements for complex multifunctional systems. Recent developments in artificial intelligence (AI) provide new opportunities to address several of these challenges by accelerating MOF design, predicting structure-property relationships, optimizing stimuli-responsive drug release, and supporting the development of personalized transdermal therapies. Overall, this review provides an integrated perspective on the design principles, therapeutic applications, and translational challenges of MOF-based transdermal systems, while outlining future directions for their successful clinical development.
Indexed as
Identifiers
42763813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.